A federal advisory committee voted Thursday to open up rules on seven peptides, including BPC-157 and TB-500. The vote was close. It is non-mandatory. The FDA has given no word on whether it will move in step with the panel. The move came after weeks of public comment sessions. Wellness backers lobbied intensely for wider access. RFK Jr. was among them. Critics say these compounds have weak safety evidence or help for most uses. The call could change how the agency handles a part of the wellness market that is scaling quickly. Market observers are watching to see if the agency adopts the plan. A spokesperson offered no set date for a next move. Critics argue the change would open up access to compounds people say help them. Safety voices warn that looser rules could leave gaps in oversight across a wide-open market. The vote only plants the seed for a shift, and the ultimate call rests with the FDA.